Affiliation:
1. From the Departments of Pharmaceutical Sciences, Biostatistics, and Hematology/Oncology, St Jude Children's Research Hospital; and the Center for Pediatric Pharmacokinetics and Therapeutics, the Department of Clinical Pharmacy, The University of Tennessee, Memphis.
Abstract
The genetic polymorphisms in human glutathione S-transferases (GST) M1 and T1 have been associated with race, disease risk, and outcome of some adult cancers. Also, there are racial differences in the incidence and characteristics of childhood acute lymphoblastic leukemia (ALL). Our objectives were to compare the frequency of the null genotype for GSTM1, GSTT1, or both in children with ALL to that in healthy controls, and to determine whether GST genotype was associated with treatment outcome and prognostic factors. We studied GSTM1 and GSTT1 genotypes in somatic cell DNA from black children and white children with ALL and in 416 healthy controls, using a polymerase chain reaction technique. Ninety of 163 (55.2%) white ALL patients and 14 of 34 (41.2%) black patients were GSTM1 null, frequencies not significantly different (P = .19) than healthy controls (53.5% in whites and 27.6% in blacks), although there was a trend toward more null genotypes in black ALL patients. Twenty-three of 163 (14.1%) white ALL patients and 12 of 34 (35.3%) black ALL patients were GSTT1 null, not different (P = .34) than the frequencies in healthy controls (15.0% in whites and 24.1% in blacks). However, the frequency of the “double-null” genotype, lacking both GSTM1 and GSTT1, was higher in black patients with ALL (8 of 34 or 23.5%) than in black controls (3.9%) (P = .0005), but this was not the case in white patients with ALL (10 of 163 or 6.1%) compared to white controls (8.0%) (P = .68). In stratified analyses, the GST double-null genotype was not associated with other characteristics that might differ between whites and blacks with ALL, such as age, T-lineage immunophenotype, presenting white blood cell count, DNA index, or insurance status. The null genotype for GSTM1, GSTT1, or both was not found to be a prognostic factor for disease-free survival or probability of hematologic remission; central nervous system relapse tended to be less common in those with the GSTM1 null genotype (P = .054) . The double-null genotype for GSTM1 and GSTT1 is more common among blacks but not whites with childhood ALL. These data suggest that GST genotype, coupled with unidentified additional risk factors, may play a role in risk of childhood ALL in American blacks.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference46 articles.
1. Infant leukemia, topoisomerase II inhibitors, and the MLL gene.;Ross;J Natl Cancer Inst,1994
2. Epidemiology of childhood leukemia, with a focus on infants.;Ross;Epidemiol Rev,1994
3. Geographical distribution of acute lymphoblastic leukaemia subtypes: Second report of the collaborative group study.;Greaves;Leukemia,1993
4. Epidemiological characteristics of childhood acute lymphocytic leukemia analysis by immunophenotype.;Buckley;Leukemia,1994
5. Maternal reproductive history and birth characteristics in childhood acute lymphoblastic leukemia.;Kaye;Cancer,1991